Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest update is out from Fagron SA ( (GB:0HNZ) ).
Fagron has released its annual report for 2024, with discussions and approval of the annual accounts scheduled for the shareholders’ meeting in May 2025. This report is available in both Dutch and English on the company’s website, potentially impacting stakeholders by providing insights into the company’s financial health and strategic direction.
More about Fagron SA
Fagron is a leading global company in pharmaceutical compounding, providing personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients across more than 30 countries. The company is based in Nazareth, Belgium, and is listed on Euronext Brussels and Euronext Amsterdam.
YTD Price Performance: 10.35%
Average Trading Volume: 3,203
Technical Sentiment Consensus Rating: Sell
Current Market Cap: €1.34B
Find detailed analytics on 0HNZ stock on TipRanks’ Stock Analysis page.